Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525025 | 0.84 | FSCN1 (0.42) | FSCN1MAPK1CYP3A4TSHRMAPT | |
| SCHEMBL29760450 | 0.84 | FSCN1 (0.42) | FSCN1MAPK1CYP3A4TSHRMAPT | |
| SCHEMBL24260461 | 0.79 | MAPK1 (0.36) | MAPK1CYP3A4TSHRMAPTGAA | |
| SCHEMBL24260342 | 0.76 | FSCN1 (0.39) | FSCN1MAPTALDH1A1TSPO | |
| SCHEMBL5685396 | 0.74 | FSCN1 (0.41) | FSCN1ALDH1A1TSPORAB9ASMN1; SMN2 | |
| SCHEMBL14156548 | 0.73 | MAPK1 (0.34) | MAPK1CYP3A4TSHRMAPTGAA | |
| SCHEMBL28388879 | 0.72 | MAPK1 (0.44) | MAPK1CYP3A4TSHRMAPTGAA | |
| SCHEMBL14048382 | 0.72 | KEAP1 (0.46) | FSCN1MAPK1MAPTGAAALDH1A1 | |
| SCHEMBL11762968 | 0.72 | FSCN1 (0.69) | FSCN1MAPK1CYP3A4TSHRMAPT | |
| SCHEMBL19848536 | 0.72 | CYP3A4 (0.48) | MAPK1CYP3A4TSHRMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365514-A1 | MACROCYCLIC COMPOUNDS | NOVO NORDISK RESEARCH CENTRE OXFORD LIMITED (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | FSCN1 4231/4885MAPK1 3627/4885CYP3A4 2325/4885 |
| US-20230365514-A1 | MACROCYCLIC COMPOUNDS | SLC2A4, GALE, MPI | FSCN1 3533/4885MAPK1 1920/4885CYP3A4 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.